Genmab — Oktober 2013
-
Our data demonstrate that the bispecific antibody EM1-mAb, generated using
Fab arm exchange, inhibited EGFR and cMet pathways simultaneously, resulting
in superior activity in cellular downstream signaling compared to the
combination of single pathway inhibitors. -
-
Sheri Moores1, Mark Chiu1, Barbara Bushey1, Kristen Chevalier1, Diana Chin1,
Susan Chippari1, Peter Haytko1, Frank McCabe1, Joost Neijssen2, Paul Parren2,
Janine Schuurman2, Sam Wu1, Ricardo Attar1, Mark Anderson1. 1Janssen R&D,
Spring House, PA; 2Genmab, Utrecht, Netherlands -
Godt fundet gentogen. Det bliver en fornøjelse at følge duobody de næste år.
-
Det er altså meget spændende at de kombi data er så stærke !!! Det er et mega + for genmab fordi GA101 er så tidlig og så giftig at den kan blive et problem i kombi
-
mon ikke arzerra er stærkest i kombi med på Idealisilib og Ibrutinib
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind